Zhi Yang, Chairman, Co-Founder

Dr. Yang currently is a general partner and executive director for BioVeda Capital, a venture capital firm focusing on investment of biotechnology in Asia Pacific and Worldwide. Dr. Yang serves on the boards of several US biotech and pharmaceutical companies. In addition, he is the associate editor for American Health Today. Prior to join BioVeda, Dr. Yang had three-year M&A experiences in Asia with H&Q Asia Pacific and its investment arm, Sinogen Inc. He had visited over hundreds of biotech and pharmaceutical companies in the region and was instrumental for the success acquisition of several biopharmaceutical companies in China. Dr. Yang has over 20 years of experience in biotechnology and biosciences. He had held senior scientific and management positions in variety of biotech and pharmaceutical companies, which include Sinogen International Ltd, Incyte Pharmaceuticals, Prolinx Inc, BioChain, Sandoz pharmaceuticals, and Systemix Inc. During his industrial stint, he had been in many different positions such as interim CEO, VP Business Development, VP of R&D, Director of Molecular Biology, Group Leader and Senior/Principle Scientist. Dr. Yang is also the principle inventor for more than 10 international patents.

Dr. Yang holds a M.A. and Ph.D. in Biochemistry and Molecular Biology from Harvard University. Walter Gilbert (Nobel laureate) was the chairman of Dr. Yang's thesis committee and Jack Strominger was his thesis advisor. From 1988 to 1991, he was a senior associate fellow and faculty member at Rockefeller University. Dr. Yang obtained his B.S. in Virology from Wuhan University in 1982. In the same year, he had been admitted as a graduate student at Institute of Virology, Chinese Academy of Medical Sciences. Dr. Yang was among the first group of CASBEA students to come to US to study biosciences.

Dr. Yang is an avid golfer.

(Back to Top)

Yuanyi Lao, CEO, Co-Founder

Mr. Lao has been serving as the Chairman & Managing Director of First Shanghai Group since 1993. He is also the Chairman of China Assets (Holdings) Ltd. Both companies are listed on The Hong Kong Stock Exchange.

Mr. Lao is a seasoned financier with over 20 years of experience in direct investment and financial management. He has an extensive track record in investment banking, venture capital investment, and asset management. Mr. Lao is a former senior policy researcher at China's National Research Center for Science & Technology & Social Development. He had also served as a senior staff officer with the PRC State Science & Technology Commission & the PRC Railway Ministry.

Mr. Lao graduated from Shanghai Fudan University and obtained his master's degree from Harvard University.

Mr. Lao enjoys golf and opera in his spare time.

(Back to Top)

Vivian Lao,General Manager

Vivian is responsible for identifying licensing and co-development opportunities for novel therapeutics as well as coordinating the operations of Crimson in Hong Kong, China, and the U.S. Prior to joining Crimson, Vivian worked in investment banking at Merrill Lynch & Co. in New York City, where she was part of the Financial Sponsors Group. Vivian graduated magna cum laude from Columbia University where she studied Engineering Management Systems.

(Back to Top)

Rankine Yeung, Chief Financial Officer

Mr. Yeung is a Director of First Shanghai Group and its associated company - China Assets. He is also Chief Financial Officer and Company Secretary of the Group. Mr. Yeung has 20 years of experience in auditing, finance and management positions. He holds professional memberships of the Association of Chartered Certified Accountants, the Hong Kong Society of Accountants, and the Taxation Institute of Hong Kong. In 2003, he obtained a Law Degree from Peking University.

(Back to Top)

Weiqin Wan, Vice President, Medicinal Chemistry

Professor Wan is a renowned expert with 40 years of experience in medicinal chemistry. Prior to joining Crimson, he was the Director of Medicinal Chemistry Institute at the No.2 Military Medical University, as well as a professor at the Pharmacology and Toxicology Lab of Navy Medical Department. He had also worked as a project scientist in anti-HIV research at York University in Canada.

Both an experienced researcher and a dedicated educator, Prof. Wan had taught medicinal chemistry for over 37 years at various universities and scientific research institutes. He had also authored, edited and translated numerous textbooks and scientific publications that are now widely used by researchers and students of medicinal chemistry in new drug design.

Prof. Wan has published more than 50 scientific papers, among which 25 were published in international academic journals such as Tetrahedron Letter, Journal of Organic Chemistry, and Journal of Medicinal Chemistry, etc. He has been rewarded patents in China, Canada, and the U.S. He has been a repeated winner of the "Outstanding Academic Paper Award"," Military Science Advancement Award" and other major national scientific accolades. Prof. Wan has also been the instructor and advisor to half a dozen post-doctorial, doctorial, and masters students.

Prof. Wan is a member of the Shanghai Pharmacy Council, Shanghai Medicinal Chemistry Committee, an editor of Chinese Journal of Medicinal Chemistry, and Pharmaceutical Practice, and serves on the scientific advisory board of several major pharmaceutical companies.

(Back to Top)

Catherine Sun, Legal Counsel

Catherine Sun is the head of China Commercial Intellectual Property Group of Deacons Hong Kong office. She serves as the acting general counsel of Crimson. Her responsibilities include providing all aspects of intellectual property and commercial legal advice to the management. Ms. Sun has acted as the general counsel for the Chinese Star Cyber Technology Ltd. in Beijing and its predecessor company since early 1990s. Ms. Sun is admitted in both U.S. (New York and Virginia) and China.

From 1998 to 2002, Ms. Sun was an attorney with Pillsbury Winthrop, LLP Washington, DC and Northern Virginia Offices. She practiced in the areas of intellectual property litigation, licensing and international trade commission matters. In 1997, she was an in house counsel for a New Jersey based telecommunication firm. In 1996, Ms. Sun served as a judicial extern at the CAFC with Honourable Judge Rader. In early 1990s, Ms. Sun practiced IP laws in Beijing for three years.

Ms. Sun is the co-chair of a two-day Doing Business in China conference sponsored by CLE International. The next conference will be held in San Francisco or Shanghai in Spring 2004. She is a frequent speaker on China IP issues.

Ms. Sun received a Bachelor of Law (LL.B.) from Peking University, and is a graduate from the George Washington University law school.

(Back to Top)